Phase I/II study of MEDI-551, a humanized monoclonal antibody targeting CD19, in subjects with relapsed or refractory advanced B-cell malignancies.
Trishna Goswami
Employment or Leadership Position - MedImmune; MedImmune
Andres Forero
Research Funding - MedImmune
Mehdi Hamadani
Honoraria - Celgene
Anne Sonet
No relevant relationships to disclose
Gregor Verhoef
No relevant relationships to disclose
Michelle A. Fanale
Research Funding - MedImmune
Celeste M. Bello
No relevant relationships to disclose
Wenmei Huang
Employment or Leadership Position - MedImmune
Bruce D. Cheson
No relevant relationships to disclose